The headline reported numbers significantly understate the underlying quality of this result, I think.
There are several features of this set of financial statements that are very positive leading indicators of continued strong growth in the years ahead.
Pity that the market valuation for the business appears to be already capturing a lot of that prospective growth.
- Forums
- ASX - By Stock
- BRG
- Ann: Half Year Ended 31 December 2017 - Appendix 4D
Ann: Half Year Ended 31 December 2017 - Appendix 4D, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$31.53 |
Change
0.450(1.45%) |
Mkt cap ! $4.538B |
Open | High | Low | Value | Volume |
$31.00 | $31.65 | $30.98 | $7.226M | 229.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 947 | $31.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$31.54 | 808 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 947 | 31.500 |
1 | 570 | 31.490 |
2 | 721 | 31.480 |
1 | 947 | 31.470 |
1 | 947 | 31.440 |
Price($) | Vol. | No. |
---|---|---|
31.540 | 808 | 2 |
31.650 | 169 | 1 |
31.660 | 947 | 1 |
31.670 | 721 | 2 |
31.680 | 947 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
BRG (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online